Posts are organized into categories for ease of navigation:
This Release contains updates to the draft version of the database. Concept mappings to RxNorm, SNOMED, and OMOP are now present for all curated therapies. We additionally curate an approval for imlunestrant from the European Medicines Agency, as well as another for belzutifan from both the European Medicines Agency and Food and Drug Administration.
This release contains updates to the draft version of the database. EGFR TKD activating variants was introduced as a biomarker and associated with regulatory approvals from the European Medicines Agency (EMA) and Health Canada (HC). No additional genomic knowledge statements were added with this release, though several were modified.
This release contains updates to the draft version of the database with FDA precision oncology approvals from February 2026. Specifically, indications and derived relationships were updated for Braftovi (encorafenib), Hernexeos (zongertinib), and Keytruda (pembrolizumab).
This release contains updates to the draft version of the database with FDA precision oncology approvals for Akeega. Additionally, the Organizations table was merged into the Agents table.